| CAT # | Khoom npe | Kev piav qhia |
| PAB 100587 | Phlorizin | Phlorizin, tseem hu ua phloridzin, yog ib qho glucoside ntawm phloretin, dihydrochalcone, tsev neeg ntawm bicyclic flavonoids, uas nyob rau hauv lem yog ib pab pawg nyob rau hauv ntau haiv neeg phenylpropanoid synthesis txoj kev nyob rau hauv cov nroj tsuag. Phlorizin yog ib qho kev sib tw inhibitor ntawm SGLT1 thiab SGLT2 vim tias nws sib tw nrog D-glucose rau kev khi rau cov cab kuj; Qhov no txo qis cov piam thaj hauv lub raum thauj, txo cov piam thaj hauv cov ntshav. Phlorizin tau kawm raws li kev kho mob muaj peev xwm rau hom 2 mob ntshav qab zib mellitus, tab sis txij li ntawd tau raug hloov pauv los ntawm kev xaiv ntau dua thiab muaj txiaj ntsig zoo dua qub, xws li canagliflozin thiab dapagliflozin. |
| PEB 0045 | Ipragliflozin | Ipragliflozin, tseem hu ua ASP1941, yog lub zog thiab xaiv SGLT2 inhibitor rau kev kho mob ntshav qab zib hom 2. Kev kho Ipragliflozin txhim kho glycemic tswj thaum ntxiv rau kev kho metformin thiab tuaj yeem cuam tshuam nrog kev poob phaus thiab txo cov ntshav siab piv rau cov placebo. Ipragliflozin txhim kho tsis tau tsuas yog hyperglycemia xwb tab sis kuj muaj ntshav qab zib / rog-uas cuam tshuam nrog metabolic abnormalities hauv hom 2 mob ntshav qab zib nas. Nws tau pom zoo siv hauv Nyij Pooj xyoo 2014 |
| PIB 100585 | Tofogliflozin | Tofogliflozin, tseem hu ua CSG 452, yog ib qho muaj zog thiab xaiv siab SGLT2 inhibitor hauv kev txhim kho kev kho mob ntshav qab zib mellitus. Tofogliflozin txhim kho glycemic tswj thiab txo lub cev hnyav hauv cov neeg mob ntshav qab zib hom 2. Tofogliflozin dose-dependently suppressed qabzib nkag mus rau hauv tubular cells. Cov piam thaj ntau dhau (30?mM) rau 4 thiab 24?h ua rau muaj zog oxidative kev nyuaj siab nyob rau hauv tubular hlwb, uas tau suppressed los ntawm kev kho mob ntawm tofogliflozin los yog antioxidant N-acetylcysteine (NAC). |
| PAB 100583 | Empagliflozin | Empagliflozin, tseem hu ua BI10773 (lub npe lag luam Jardiance), yog cov tshuaj pom zoo rau kev kho mob ntshav qab zib hom 2 hauv cov neeg laus xyoo 2014. Nws tau tsim los ntawm Boehringer Ingelheim thiab Eli Lilly thiab Tuam Txhab. Empagliflozin yog ib qho inhibitor ntawm sodium glucose co-transporter-2 (SGLT-2), thiab ua rau cov piam thaj hauv cov ntshav nqus los ntawm ob lub raum thiab tshem tawm hauv cov zis. Empagliflozin yog ib qho inhibitor ntawm sodium glucose co-transporter-2 (SGLT-2), uas pom yuav luag tshwj xeeb hauv cov tubules ze ntawm nephronic Cheebtsam hauv ob lub raum. SGLT-2 suav txog li 90 feem pua ntawm cov piam thaj reabsorption rau hauv cov ntshav. |
| PAB 100582 | Canagliflozin | Canagliflozin (INN, lub npe lag luam Invokana) yog cov tshuaj kho mob ntshav qab zib hom 2. Nws tau tsim los ntawm Mitsubishi Tanabe Pharma thiab tau ua lag luam raws li daim ntawv tso cai los ntawm Janssen, ib feem ntawm Johnson & Johnson. Canagliflozin yog ib qho inhibitor ntawm subtype 2 sodium-glucose thauj protein (SGLT2), uas yog lub luag haujlwm rau tsawg kawg 90% ntawm cov piam thaj reabsorption hauv lub raum. Thaiv cov khoom thauj no ua rau cov ntshav qabzib raug tshem tawm los ntawm cov zis. Thaum Lub Peb Hlis 2013, canagliflozin tau los ua thawj SGLT2 inhibitor kom pom zoo hauv Tebchaws Meskas. |
| PIB 0003 | Dapagliflozin | Dapagliflozin, tseem hu ua BMS-512148, yog ib qho tshuaj siv los kho mob ntshav qab zib hom 2 tau pom zoo hauv xyoo 2012 los ntawm FDA. Dapagliflozin inhibits subtype 2 ntawm sodium-glucose thauj proteins (SGLT2) uas yog lub luag haujlwm rau tsawg kawg 90% ntawm cov piam thaj reabsorption hauv lub raum. Thaiv qhov kev thauj mus los no ua rau cov ntshav qabzib raug tshem tawm los ntawm cov zis. Hauv kev sim tshuaj, dapagliflozin txo HbA1c los ntawm 0.6 piv rau cov placebo feem pua ntawm cov ntsiab lus thaum ntxiv rau metformin. |
